Hansa Biopharma announces participation in Fall investor conferences and provides updated financial calendar
February 16, 2022
139
LUND, Sweden , Aug. 31, 2021 /PRNewswire/ — Hansa Biopharma AB “Hansa”, (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced that the Company’s management team will present at the following upcoming investor conferences during September 2021:
Access to content from the Arctic Knowledge Archives is available to subscribers only.
Please sign in to continue, or choose your subscription for unlimited access.
All memberships are considered donations to support this non-profit effort. Institutions and groups should contact us directly for pricing.
Already a subscriber? Log in
Membership
You may select only one level from this group.
Individual Annual
$150.00
Year
Individual Monthly
$15.00
Month
